Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

602 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
Feagan BG, Sandborn WJ, D'Haens G, Panés J, Kaser A, Ferrante M, Louis E, Franchimont D, Dewit O, Seidler U, Kim KJ, Neurath MF, Schreiber S, Scholl P, Pamulapati C, Lalovic B, Visvanathan S, Padula SJ, Herichova I, Soaita A, Hall DB, Böcher WO. Feagan BG, et al. Lancet. 2017 Apr 29;389(10080):1699-1709. doi: 10.1016/S0140-6736(17)30570-6. Epub 2017 Apr 12. Lancet. 2017. PMID: 28411872 Free article. Clinical Trial.
Methotrexate in refractory Crohn's disease.
Vandeputte L, D'Haens G, Baert F, Rutgeerts P. Vandeputte L, et al. Inflamm Bowel Dis. 1999 Feb;5(1):11-5. doi: 10.1097/00054725-199902000-00002. Inflamm Bowel Dis. 1999. PMID: 10028444
Mycophenolate mofetil in Crohn's disease.
Rampton DS, Neurath MF, Almer S, D'Haens G, Petritsch W, Stange EF. Rampton DS, et al. Lancet. 2000 Jul 8;356(9224):163-4. doi: 10.1016/s0140-6736(05)73176-7. Lancet. 2000. PMID: 10963270 Clinical Trial. No abstract available.
602 results